David Sallman, MD, on Updates From the AMELI-01 Trial of UCART123v1.2 for AML
The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.
David Sallman, MD, on Advantages of Allogeneic CAR T-Cell Therapy in AML
The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed unmet needs in acute myeloid leukemia and how UCART123v1.2 may address these.
